The PML-RARα Fusion Protein and Targeted Therapy for Acute Promyelocytic Leukemia

REFERENCES

• de The, H., Lavau, C., Marchio, A., Chomienne, C., Degos, L. and Dejean, A. (1991) "The PML-RAR alpha fusion mRNA generated by the t(15;17) translocation in acute promyelocytic leukemia encodes a functionally altered RAR", Cell, 66, 675–684.
   Google Scholar
• Kakizuka, A., Miller, W.H., Jr., Umesono, K., Warrell, R.P., Jr., Frankel, S.R., Murty, V.V., et al. (1991) "Chromosomal translo-cation t(15;17) in human acute promyelocytic leukemia fuses RAR alpha with a novel putative transcription factor, PML", Cell, 66, 663— 674.
   Google Scholar
• Chen, Z., Brand, N.J., Chen, A., Chen, S.J., Tong, J.H., Wang, Z.Y., et al. (1993) "Fusion between a novel Kruppel-like zinc finger gene and the retinoic acid receptor-alpha locus due to a variant t(11;17) translocation associated with acute promyelocytic leukae-mia", EMBO J., 12, 1161 — 1167.
   Google Scholar
• Wells, R.A., Catzavelos, C. and Kamel Reid, S. (1997) "Fusion of retinoic acid receptor alpha to NuMA, the nuclear mitotic apparatus protein, by a variant translocation in acute promyelo-cytic leukaemia", Nat. Genet., 17, 109–113.
   PubMed Web of Science ®Google Scholar
• Redner, R.L., Rush, E.A., Faas, S., Rudert, W.A. and Corey, S.J. (1996) "The t(5;17) variant of acute promyelocytic leukemia expresses a nucleophosmin-retinoic acid receptor fusion", Blood, 87, 882–886.
   PubMed Web of Science ®Google Scholar
• Arnould, C., Philippe, C., Bourdon, V., Gr goire, M.J., Berger, R. and Jonveaux, P. (1999) "The signal transducer and activator of transcription STAT5b gene is a new partner of retinoic acid receptor alpha in acute promyelocytic-like leukaemia", Hum. MoL Genet., 8, 1741–1749.
   Web of Science ®Google Scholar
• He, L.Z., Tribioli, C., Rivi, R., Peruzzi, D., Pelicci, P.G., Soares, V., et al. (1997) "Acute leukemia with promyelocytic features in PML/RARalpha transgenic mice", Proc. Natl. Acad. Sci. USA, 94, 5302— 5307.
   PubMed Web of Science ®Google Scholar
• Grisolano, J.L., Wesselschmidt, R.L., Pelicci, P.G. and Ley, T.J. (1997) "Altered myeloid development and acute leukemia in transgenic mice expressing PML-RAR alpha under control of cathepsin G regulatory sequences", Blood, 89, 376— 387.
   Google Scholar
• He, L., Bhaumik, M., Tribioli, C., Rego, E.M., Ivins, S., Zelent, A. and Pandolfi, P.P. (2000) "Two critical hits for promyelocytic leukemia", MoL Cell, 6, 1131–1134.
   PubMed Web of Science ®Google Scholar
• Pandolfi, P.P. (2001) "In vivo analysis of the molecular genetics of acute promyelocytic leukemia", Oncogene, 20, 5726–5735.
   Google Scholar
• Pandolfi, P.P. (2001) "Oncogenes and tumor suppressors in the molecular pathogenesis of acute promyelocytic leukemia", Hum. Mol. Genet., 10, 769–775.
   Google Scholar
• Chang, K.S., Stass, S.A., Chu, D.T., Deaven, L.L., Trujillo, J.M. and Freireich, E.J. (1992) "Characterization of a fusion cDNA (RARA/myl) transcribed from the t(15;17) translocation break-point in acute promyelocytic leukemia", MoL Cell. Biol., 12, 800 — 810.
   Google Scholar
• Biondi, A., Rambaldi, A., Pandolfi, P.P., Rossi, V., Giudici, G., Alcalay, M., et al. (1992) "Molecular monitoring of the myl/retinoic acid receptor-alpha fusion gene in acute promyelo-cytic leukemia by polymerase chain reaction", Blood, 80, 492 — 497.
   Google Scholar
• Pandolfi, P.P., Alcalay, M., Longo, L., Fagioli, M., Zangrilli, D., Grignani, F., et al. (1992) "Molecular genetics of the t(15;17) of acute promyelocytic leukemia (APPL)", Leukemia, 6\(Suppl. 3), 120s–122s.
   Google Scholar
• Gallagher, R.E., Willman, C.L., Slack, J.L., Andersen, J.W., Li, Y.P., Viswanatha, D., et al. (1997) "Association of PML-RAR alpha fusion mRNA type with pretreatment hematologic characteristics but not treatment outcome in acute promyelo-cytic leukemia: an intergroup molecular study", Blood, 90, 1656 — 1663.
   Google Scholar
• Grignani, F., De Matteis, S., Nervi, C., Tomassoni, L., Gelmetti, V., Cioce, M., et al. (1998) "Fusion proteins of the retinoic acid receptor-alpha recruit histone deacetylase in promyelocytic leu-kaemia", Nature, 391, 815 — 818.
   Google Scholar
• Perez, A., Kastner, P., Sethi, S., Lutz, Y., Reibel, C. and Chambon, P. (1993) "PMLRAR homodimers: distinct DNA binding properties and heteromeric interactions with RXR", EMBO J., 12, 3171–3182.
   PubMed Web of Science ®Google Scholar
• Koken, M.H., Linares Cruz, G., Quignon, F., Viron, A., Chelbi Alix, M.K., Sobczak Thepot, J., et al. (1995) "The PML growth-suppressor has an altered expression in human oncogenesis", Oncogene, 10, 1315–1324.
   Google Scholar
• Hong, S.H., David, G., Wong, C.W., Dejean, A. and Privalsky, M.L. (1997) "SMRT corepressor interacts with PLZF and with the PML-retinoic acid receptor alpha (RARalpha) and PLZF-RARalpha oncoproteins associated with acute promyelocytic leukemia", Proc. Natl. Acad. Sci. USA, 94, 9028 — 9033.
   PubMed Web of Science ®Google Scholar
• Lin, R.J., Nagy, L., Inoue, S., Shao, W., Miller, W.H., Jr. and Evans, R.M. (1998) "Role of the histone deacetylase complex in acute promyelocytic leukaemia", Nature, 391, 811–814.
   Google Scholar
• Guidez, F., Ivins, S., Zhu, J., Soderstrom, M., Waxman, S. and Zelent, A. (1998) "Reduced retinoic acid-sensitivities of nuclear receptor corepressor binding to PML- and PLZF-RARalpha underlie molecular pathogenesis and treatment of acute promye-locytic leukemia", Blood, 91, 2634 — 2642.
   Google Scholar
• He, L.Z., Guidez, F., Tribioli, C., Peruzzi, D., Ruthardt, M., Zelent, A. and Pandolfi, P.P. (1998) "Distinct interactions of PML-RARalpha and PLZF-RARalpha with co-repressors determine differential responses to RA in APL", Nat. Genet., 18, 126— 135.
   PubMed Web of Science ®Google Scholar
• Melnick, A. and Licht, J.D. (1999) "Deconstructing a disease: RARalpha, its fusion partners, and their roles in the pathogenesis of acute promyelocytic leukemia", Blood, 93, 3167— 3215.
   Google Scholar
• Lin, R.J. and Evans, R.M. (2000) "Acquisition of oncogenic potential by RAR chimeras in acute promyelocytic leukemia through formation of homodimers", MoL Cell, 5, 821-830. Hauksdottir, H. and Privalsky, M.L. (2001) "DNA recognition by the aberrant retinoic acid receptors implicated in human acute promyelocytic leukemia". Cell Growth Differ., 12, 85–98.
   Google Scholar
• Piazza, F., Gurrieri, C. and Pandolfi, P.P. (2001) "The theory of APL", Oncogene, 20, 7216–7222.
   PubMed Web of Science ®Google Scholar
• Mistry, A.R., Pedersen, E.W., Solomon, E. and Grimwade, D. (2003) "The molecular pathogenesis of acute promyelocytic leukaemia: implications for the clinical management of the disease", Blood Rev., 17, 71 — 97.
   Google Scholar
• Cunningham, I., Gee, T.S., Reich, L.M., Kempin, S.J., Naval, A.N. and Clarkson, B.D. (1989) "Acute promyelocytic leukemia: treatment results during a decade at Memorial Hospital", Blood, 73, 1116–1122.
   Google Scholar
• Head, D., Kopecky, K.J., Weick, J., Files, J.C., Ryan, D., Foucar, K., et al. (1995) "Effect of aggressive daunomycin therapy on survival in acute promyelocytic leukemia", Blood, 86, 17 17 — 1728.
   Web of Science ®Google Scholar
• Degos, L., Dombret, H., Chomienne, C., Daniel, M.T., Miclea, J.M., Chastang, C., et al. (1995) "All-trans-retinoic acid as a differentiating agent in the treatment of acute promyelocytic leukemia [see comments]", Blood, 85, 2643–2653.
   Google Scholar
• Castaigne, S. and Degos, L. (1995) "[Treatment of acute promyelocytic leukemia by all trans retinoic acid]", C. R. Seances Soc. Biol. Fil., 189, 515–520.
   PubMedGoogle Scholar
• Fenaux, P., Chomienne, C. and Degos, L. (2001) "All-trans retinoic acid and chemotherapy in the treatment of acute promyelocytic leukemia", Semin. HematoL, 38, 13–25.
   Web of Science ®Google Scholar
• Huang, ME., Ye, Y.C., Chen, SR., Chai, J.R., Lu, J.X., Zhoa, L., et al. (1988) "Use of all-trans retinoic acid in the treatment of acute promyelocytic leukemia", Blood, 72, 567— 572.
   Google Scholar
• Castaigne, S., Chomienne, C., Daniel, MT., Ballerini, P., Berger, R., Fenaux, P. and Degos, L. (1990) "All-trans retinoic acid as a differentiation therapy for acute promyelocytic leukemia. I. Clinical results [see comments]", Blood, 76, 1704 — 1709.
   Google Scholar
• Warrell, R.P., Jr., Frankel, SR., Miller, W.H., Jr., Scheinberg, D.A., Itri, L.M., Hittelman, W.N., et al. (1991) "Differentiation therapy of acute promyelocytic leukemia with tretinoin (all-trans-retinoic acid)", N. Engl. J. Med., 324, 1385 — 1393.
   Google Scholar
• Fenaux, P., Chastang, C., Chevret, S., Sanz, M., Dombret, H., Archimbaud, E., et al. (1999) "A randomized comparison of all transretinoic acid (ATRA) followed by chemotherapy and ATRA plus chemotherapy and the role of maintenance therapy in newly diagnosed acute promyelocytic leukemia. The European APL Group", Blood, 94, 1192–1200.
   PubMed Web of Science ®Google Scholar
• Warrell, R.P., Jr., Maslak, P., Eardley, A., Heller, G., Miller, W.H., Jr. and Frankel, S.R. (1994) "Treatment of acute promyelocytic leukemia with all-trans retinoic acid: an update of the New York experience", Leukemia, 8, 929–933.
   PubMed Web of Science ®Google Scholar
• Frankel, SR., Eardley, A., Heller, G., Berman, E., Miller, W.H., Jr., Dmitrovsky, E. and Warrell, R.P., Jr. (1994) "All-trans retinoic acid for acute promyelocytic leukemia. Results of the New York Study", Ann. Intern. Med., 120, 278–286.
   PubMed Web of Science ®Google Scholar
• Frankel, S.R., Eardley, A., Heller, G., Berman, E., Miller, W.H., Jr., Dmitrovsky, E. andWarrell, R.P., Jr. (1994) "All-trans retinoic acid for acute promyelocytic leukemia. Results of the New York Study", Ann. Intern. Med., 120, 278 – 286.
   Google Scholar
• Delva, L., Comic, M., Balitrand, N., Guidez, F., Miclea, J.M., Delmer, A., et al. (1993) "Resistance to all-trans retinoic acid (ATRA) therapy in relapsing acute promyelocytic leukemia: study of in vitro ATRA sensitivity and cellular retinoic acid binding protein levels in leukemic cells [see comments]", Blood, 82, 2175 — 2181.
   Google Scholar
• Niu, C., Yan, H., Yu, T., Sun, H.P., Liu, J.X., Li, X.S., et al. (1999) "Studies on treatment of acute promyelocytic leukemia with arsenic trioxide: remission induction, follow-up, and molecular monitoring in 11 newly diagnosed and 47 relapsed acute promyelocytic leukemia patients", Blood, 94, 3315 — 3324.
   Google Scholar
• Soignet, S.L., Maslak, P., Wang, Z.G., Jhanwar, S., Calleja, E., Dardashti, L.J., et al. (1998) "Complete Remission after Treatment of Acute Promyelocytic Leukemia with Arsenic Trioxide", N. Engl. J. Med., 339, 1341–1348.
   Google Scholar
• Zhang, P., Wang, S.Y. and Hu, X. (1996) "Arsenic trioxide treated 72 cases of acute promyelocytic leukemia", Chin. J. Hematol., 17, 58–61.
   Google Scholar
• Huang, S.Y., Chang, C.S., Tang, J.L., Tien, H.F., Kuo, T.L., Huang, S.F., et al. (1998) "Acute and chronic arsenic poisoning associated with treatment of acute promyelocytic leukaemia", Br. J. Haematol., 103, 1092–1095.
   Web of Science ®Google Scholar
• Raelson, iv., Nervi, C., Rosenauer, A., Benedetti, L., Monczak, Y., Pearson, M., et al. (1996) "The PML/RAR alpha oncoprotein is a direct molecular target of retinoic acid in acute promyelocytic leukemia cells", Blood, 88, 2826–2832.
   Google Scholar
• Chomienne, C., Balitrand, N., Ballerini, P., Castaigne, S., de The, H. and Degos, L. (1991) "All-trans retinoic acid modulates the retinoic acid receptor-alpha in promyelocytic cells", J. Clin. Invest., 88, 2150–2154.
   Google Scholar
• Chen, G.Q., Zhu, J., Shi, X.G., Ni, J.H., Zhong, H.J., Si, G.Y., et al. (1996) "In vitro studies on cellular and molecular mechanisms of arsenic trioxide (As203) in the treatment of acute promyelocytic leukemia: As203 induces NB4 cell apoptosis with downregulation of Bc1-2 expression and modulation of PML-RAR alpha/PML proteins", Blood, 88, 1052–1061.
   Google Scholar
• Zhu, J., Koken, M.H., Quignon, F., Chelbi-Alix, M.K., Degos, L., Wang, Z.Y., et al. (1997) "Arsenic-induced PML targeting onto nuclear bodies: implications for the treatment of acute promyelocytic leukemia", Proc. Natl. Acad. Sci. USA, 94, 3978 — 3983.
   Google Scholar
• Jing, Y., Wang, L., 3Cia, L.J., Chen, G.Q., Chen, Z., Miller, W.H. and Waxman, S. (2001) "Combined effect of all-trans retinoic acid and arsenic trioxide in acute promyelocytic leukemia cells in vitro and in vivo", Blood, 97, 264–269.
   PubMed Web of Science ®Google Scholar
• Lin, R.J., Sternsdorf, T., Tini, M. and Evans, R.M. (2001) "Transcriptional regulation in acute promyelocytic leukemia", Oncogene, 20, 7204–7215.
   PubMed Web of Science ®Google Scholar
• Guidez, F. and Zelent, A. (2001) "Role of nuclear receptor corepressors in leukemogenesis", Curr. Top. Microbiol. Immunol., 254, 165–185.
   Web of Science ®Google Scholar
• Zelent, A., Guidez, F., Melnick, A., Waxman, S. and Licht, J.D. (2001) "Translocations of the RARalpha gene in acute promye-locytic leukemia", Oncogene, 20, 7186–7203.
   PubMed Web of Science ®Google Scholar
• Miller, W.H.J. and Waxman, S. (2002) "Differentiation induction as a treatment for hematologic malignancies", Oncogene, 21, 3496— 3506.
   Google Scholar
• Benoit, G.R., Tong, J.H., Balajthy, Z. and Lanotte, M. (2001) "Exploring (novel) gene expression during retinoid-induced maturation and cell death of acute promyelocytic leukemia", Semin. Hematol., 38, 71–85.
   Web of Science ®Google Scholar
• Liu, TX., Zhang, J.W., Tao, J., Zhang, R.B., Zhang, Q.H., Zhao, C.J., et al. (2000) "Gene Expression networks underlying retinoic acid-induced differentiation of acute promyelocytic leukemia cells", Blood, 96, 1496 — 1504.
   Google Scholar
• Hughes, T.R., Mao, M., Jones, A.R., et al. (2001) "Expression profiling using microarrays fabricated by an ink-jet oligonucleotide synthesizer", Nat. Biotechnol., 19, 342— 347.
   Google Scholar
• Morosetti, R., Park, D.J., Chumakov, AM., Grillier, I., Shiohara, M., Gombart, A.F., et al. (1997) "A novel, myeloid transcription factor, C/EBP epsilon, is upregulated during granulocytic, but not monocytic, differentiation", Blood, 90, 2591–2600.
   Google Scholar
• Chumakov, A.M., Grillier, I., Chumakova, E., Chih, D., Slater, J. and Koeffler, H.P. (1997) "Cloning of the novel human myeloid-cell-specific C/EBP-epsilon transcription factor", Mol. Cell. Biol., 17, 1375–1386.
   Web of Science ®Google Scholar
• Park, D.J., Chumakov, AM., Vuong, PT., Chih, D.Y., Gombart, A.F., Miller, W.H.J. and Koeffier, H.P. (1999) "CCAAT/enhancer binding protein epsilon is a potential retinoid target gene in acute promyelocytic leukemia treatment", J. Clin. Invest., 103, 1399 — 1408.
   Google Scholar
• Watanabe, N., Nakajima, H., Ikeda, Y. and Handa, M. (2000) "A critical role for CAAT-enhancer binding protein epsilon in cell cycle arrest and apoptosis during myeloid differentiation", Blood, 96, 284a.
   Google Scholar
• Khanna-Gupta, A., Zibello, T., Lekstrom-Himes, J. and Berliner, N. (2000) "C/EBPc mediate myeloid differentiation and is regulated by the CCAAT displacement protein (CDP/cut) in 32Dc13 cells", Blood, 96, 282a.
   Google Scholar
• Truong, B.T., Lee, Y.J., Lodie, T.A., Park, D.J., Perrotti, D., Watanabe, N., et al. (2003) "CCAAT/Enhancer binding proteins repress the leukemic phenotype of acute myeloid leukemia", Blood, 101, 1141–1148.
   Google Scholar
• Duprez, E.A., Koch, H. and Tenen, D.G. (2001) "C/EBPbeta is an important target of PML/RARA during ATRA-induced differ-entiation of APL cells", Blood, 98, 833a.
   Google Scholar
• Dyck, J.A., Maul, G.G., Miller, W.H., Jr., Chen, J.D., Kakizuka, A. and Evans, R.M. (1994) "A novel macromolecular structure is a target of the promyelocyte-retinoic acid receptor oncoprotein", Cell, 76, 333–343.
   Google Scholar
• Yoshida, H., Kitamura, K., Tanaka, K., Omura, S., Miyazaki, T., Hachiya, T., et al. (1996) "Accelerated degradation of PML-retinoic acid receptor alpha (PML-RARA) oncoprotein by all-trans-retinoic acid in acute promyelocytic leukemia: possible role of the proteasome pathway", Cancer Res., 56, 2945–2948.
   PubMed Web of Science ®Google Scholar
• Duprez, E., Lillehaug, J.R., Naoe, T. and Lanotte, M. (1996) "cAMP signalling is decisive for recovery of nuclear bodies (PODs) during maturation of RA-resistant t(15;17) promyelocytic leuke-mia NB4 cells expressing PML-RAR alpha", Oncogene, 12, 2451 — 2459.
   Google Scholar
• Duprez, E., Lillehaug, J.R., Gaub, M.P. and Lanotte, M. (1996) "Differential changes of retinoid-X-receptor (RXR alpha) and its RAR alpha and PML-RAR alpha partners induced by retinoic acid and cAMP distinguish maturation sensitive and resistant t(15;17) promyelocytic leukemia NB4 cells", Oncogene, 12, 2443 — 2450.
   Google Scholar
• Zhu, J., Gianni, M., Kopf, E., Honore, N., Chelbi-Alix, M., Koken, M., et al. (2000) "Retinoic acid induces proteasome-dependent degradation of retinoic acid receptor alpha (RARalpha) and oncogenic RARalpha fusion proteins", Proc. Natl. Acad. Sci. USA, 96, 14807–14812.
   PubMed Web of Science ®Google Scholar
• Nervi, C., Ferrara, F.F., Fanelli, M., Rippo, MR., Tomassini, B., Ferrucci, P.F., et al. (1998) "Caspases Mediate Retinoic Acid-Induced Degradation of the Acute Promyelocytic Leukemia PML/ RARalpha Fusion Protein", Blood, 92, 2244–2251.
   Google Scholar
• Gianni, M., Koken, M.H., Chelbi-Alix, M.K., Benoit, G., Lanotte, M., Chen, Z. and de The, H. (1998) "Combined arsenic and retinoic acid treatment enhances differentiation and apoptosis in arsenic-resistant NB4 cells", Blood, 91, 4300–4310.
   PubMed Web of Science ®Google Scholar
• Fanelli, M., Nervi, C., Pelicci, G. and Gambacorti-Passerini, C. (1997) "Constitutive degradation of the PML/RARa protein is present in retinoic acid (RA)-resistant acute promyelocytic leukemia cells and involves the proteasome proteolytic pathway", Blood, 90\(Supp 1), 70a.
   PubMed Web of Science ®Google Scholar
• Idres, N., Benoit, G., Flexor, M.A., Lanotte, M. and Chabot, G.G. (2001) "Granulocytic differentiation of human NB4 promyelocytic leukemia cells induced by all-trans retinoic acid metabolites", Cancer Res., 61, 700–705.
   PubMed Web of Science ®Google Scholar
• Benoit, G., Altucci, L., Flexor, M., Ruchaud, S., Lillehaug, J., Raffelsberger, W., et al. (1999) "RAR-independent RXR signaling induces t(15;17) leukemia cell maturation", EMBO J., 18, 7011 — 7018.
   Google Scholar
• Jing, Y., 3Cia, L., Lu, M. and Waxman, S. (2003) "The cleavage product APML-RARa contributes to all-trans retinoic acid-mediated differentiation in acute promyelocytic leukemia cells", Oncogene, 22, 4083 — 4091.
   Google Scholar
• Radomska, H.S., Huettner, CS., Zhang, P., Cheng, T., Scadden, D.T. and Tenen, D.G. (1998) "CCAAT/enhancer binding protein alpha is a regulatory switch sufficient for induction of granulocytic development from bipotential myeloid progenitors", Mol. Cell. Biol., 18, 4301 —4314.
   Web of Science ®Google Scholar
• Lodie, T.A., Behre, G., Zhang, P., Pelicci, P.G. and Tenen, D.G. (1998) "Expression of the leukemic fusion protein, PML/RARa inhibits C/EBPalpha DNA binding and blocks granulocytic differentiation", Blood, 92, 211a.
   Google Scholar
• Tenen, D.G. (2001) "Abnormalities of the CEBP alpha transcrip-tion factor: a major target in acute myeloid leukemia", Leukemia, 15, 688 — 689.
   Google Scholar
• Dermime, S., Grignani, F., Clerici, M., Nervi, C., Sozzi, G., Talamo, G.P., et al. (1993) "Occurrence of resistance to retinoic acid in the acute promyelocytic leukemia cell line NB4 is associated with altered expression of the pml/RAR alpha protein", Blood, 82, 1573— 1577.
   Google Scholar
• Dermime, S., Grignani, F., Rogaia, D., Liberatore, C., Marchesi, E. and Gambacorti Passerini, C. (1995) "Acute promyelocytic leukaemia cells resistant to retinoic acid show further perturbation of the RAR alpha signal transduction system", Leuk. Lymphoma, 16, 289 — 295.
   PubMed Web of Science ®Google Scholar
• Shao, W., Fanelli, M., Ferrara, F.F., Riccioni, R., Rosenauer, A., Davison, K., et al. (1998) "Arsenic trioxide as an inducer of apoptosis and loss of PML/RAR alpha protein in acute promyelocytic leukemia cells [see comments]", J. Natl. Cancer Inst., 90, 124— 133.
   Google Scholar
• Grignani, F., Ferrucci, P.F., Testa, U., Talamo, G., Fagioli, M., Alcalay, M., et al. (1993) "The acute promyelocytic leukemia-specific PML-RAR alpha fusion protein inhibits differentiation and promotes survival of myeloid precursor cells", Cell, 74, 423 — 431.
   Google Scholar
• Ruchaud, S., Duprez, E., Gendron, MC., Houge, G., Genieser, HG., Jastorff, B., et al. (1994) "Two distinctly regulated events, priming and triggering, during retinoid-induced maturation and resistance of NB4 promyelocytic leukemia cell line", Proc. Natl. Acad. Sci. USA, 91, 8428–8432.
   PubMed Web of Science ®Google Scholar
• Doucas, V. and Evans, R.M. (1996) "The PML nuclear compart-ment and cancer", Biochim. Biophys. Acta, 1288, M25— M29.
   PubMed Web of Science ®Google Scholar
• Boddy, M.N., Duprez, E., Borden, K.L. and Freemont, P.S. (1997) "Surface residue mutations of the PML RING finger domain alter the formation of nuclear matrix-associated PML bodies", J. Cell. Sci., 110, 2197 — 2205.
   PubMed Web of Science ®Google Scholar
• Jing, Y., Xia, L. and Waxman, S. (2002) "Targeted removal of PML-RARalpha protein is required prior to inhibition of histone deacetylase for overcoming all-trans retinoic acid differentiation resistance in acute promyelocytic leukemia", Blood,100, 1008 — 1013.
   Google Scholar
• Gallagher, R.E. (2002) "Retinoic acid resistance in acute promye-locytic leukemia", Leukemia, 16, 1940–1958.
   Web of Science ®Google Scholar
• Roussel, M.J. and Lanotte, M. (2001) "Maturation sensitive and resistant t(15;17) NB4 cell lines as tools for APL physiopathology: nomenclature of cells and repertory of their known genetic alterations and phenotypes", Oncogene, 20, 7287–7291.
   Google Scholar
• Kitamura, K., Kiyoi, H., Yoshida, H., Saito, H., Ohno, R. and Naoe, T. (1997) "Mutant AF-2 domain of PML-RARalpha in retinoic acid-resistant NB4 cells: differentiation induced by RA is triggered directly through PML-RARalpha and its down-regula-tion in acute promyelocytic leukemia", Leukemia, 11, 1950— 1956.
   Google Scholar
• Shao, W., Benedetti, L., Lamph, W.W., Nervi, C. and Miller, W.H., Jr. (1997) "A retinoid-resistant acute promyelocytic leukemia subclone expresses a dominant negative PML-RAR alpha mutation", Blood, 89, 4282–4289.
   PubMed Web of Science ®Google Scholar
• Nason-Burchenal, K., Allopenna, J., Begue, A., Stehelin, D., Dmitrovsky, E. and Martin, P. (1998) "Targeting of PML/ RARalpha is lethal to retinoic acid-resistant promyelocytic leukemia cells", Blood, 92, 1758— 1767.
   Google Scholar
• Duprez, E., Benoit, G., Flexor, M., Lillehaug, J.R. and Lanotte, M. (2000) "A mutated PML/RARA found in the retinoid maturation resistant NB4 subclone, NB4-R2, blocks RARA and wild-type PML/RARA transcriptional activities", Leukemia, 14, 255 — 261.
   Google Scholar
• Takayama, N., Kizaki, M., Hida, T., Kinjo, K. and Ikeda, Y. (2001) "Novel mutation in the PML/RARalpha chimeric gene exhibits dramatically decreased ligand-binding activity and confers acquired resistance to retinoic acid in acute promyelocytic leukemia", Exp. Hematol., 29, 864–872.
   Web of Science ®Google Scholar
• Ding, W., Li, Y.P., Nobile, L.M., Grills, G., Carrera, I., Paietta, E., et al. (1998) "Leukemic cellular retinoic acid resistance and missense mutations in the PML-RARalpha fusion gene after relapse of acute promyelocytic leukemia from treatment with all-trans retinoic acid and intensive chemotherapy", Blood, 92, 1172 — 1183.
   Google Scholar
• Imaizumi, M., Suzuki, H., Yoshinari, M., Sato, A., Saito, T., Sugawara, A., et al. (1998) "Mutations in the E-domain of RAR portion of the PML/RAR chimeric gene may confer clinical resistance to all-trans retinoic acid in acute promyelocytic leukemia", Blood, 92, 374— 382.
   Google Scholar
• Fanelli, M., Minucci, S., Gelmetti, V., Nervi, C., Gambacorti-Passerini, C. and Pelicci, P.G. (1999) "Constitutive degradation of PML/RARalpha through the proteasome pathway mediates retinoic acid resistance", Blood, 93, 1477 — 1481.
   Google Scholar
• Rosenauer, A., Raelson, J.V., Nervi, C., Eydoux, P., DeBlasio, A. and Miller, W.H., Jr. (1996) "Alterations in expression, binding to ligand and DNA, and transcriptional activity of rearranged and wild-type retinoid receptors in retinoid-resistant acute promyelo-cytic leukemia cell lines", Blood, 88, 2671–2682.
   PubMed Web of Science ®Google Scholar
• Nason Burchenal, K., Maerz, W., Albanell, J., Allopenna, J., Martin, P., Moore, M.A. and Dmitrovsky, E. (1997) "Common defects of different retinoic acid resistant promyelocytic leukemia cells are persistent telomerase activity and nuclear body disorga-nization", Differentiation, 61, 321–331.
   Google Scholar
• Pandolfi, P.P. (2001) "Histone deacetylases and transcriptional therapy with their inhibitors", Cancer Chemother. Pharmacol., 48\(Suppl. 1), S17 — S19.
   PubMed Web of Science ®Google Scholar
• Chen, A., Licht, J.D., Wu, Y., Hellinger, N., Scher, W. and Waxman, S. (1994) "Retinoic acid is required for and potentiates differentiation of acute promyelocytic leukemia cells by nonreti-noid agents", Blood, 84, 2122–2129.
   Google Scholar
• Kosugi, H., Towatari, M., Hatano, S., Kitamura, K., Kiyoi, H., Kinoshita, T., et al. (1999) "Histone deacetylase inhibitors are the potent inducer/enhancer of differentiation in acute myeloid leukemia: a new approach to anti-leukemia therapy", Leukemia, 13, 1316 — 1324.
   Google Scholar
• Warrell, R.P.J., He, L.Z., Richon, V., Calleja, E. and Pandolfi, P.P. (1998) "Therapeutic targeting of transcription in acute promyelo-cytic leukemia by use of an inhibitor of histone deacetylase", J. Natl. Cancer Inst., 90, 1621–1625.
   Web of Science ®Google Scholar
• Novick, S., Camacho, L., Gallagher, R., Chanel, S., Ho, R., Tolentino, T., et al. (1999) "Initial clinical evaluation of 'transcription therapy' for cancer: All-trans retinoic acid plus phenylbutyrate", Blood, 94\(Suppl. 1), 60a.
   Google Scholar
• Kitamura, K., Hoshi, S., Koike, M., Kiyoi, H., Saito, H. and Naoe, T. (2000) "Histone deacetylase inhibitor but not arsenic trioxide differentiates acute promyelocytic leukaemia cells with t(11;17) in combination with all-trans retinoic acid", Br. J. Haematol., 108, 696–702.
   Web of Science ®Google Scholar
• He, L.Z., Tolentino, T., Grayson, P., Zhong, S., Warrell, R.P., Jr., Rifkind, R.A., et al. (2001) "Histone deacetylase inhibitors induce remission in transgenic models of therapy-resistant acute promye-locytic leukemia", J. Clin. Invest., 108, 1321–1330.
   PubMed Web of Science ®Google Scholar
• Licht, J.D., Chomienne, C., Goy, A., Chen, A., Scott, A.A., Head, DR., et al. (1995) "Clinical and molecular characterization of a rare syndrome of acute promyelocytic leukemia associated with translocation (11;17)", Blood, 85, 1083–1094.
   PubMed Web of Science ®Google Scholar
• Koken, M.H., Daniel, MT., Gianni, M., Zelent, A., Licht, J., Buzyn, A., et al. (1999) "Retinoic acid, but not arsenic trioxide, degrades the PLZF/RARalpha fusion protein, without inducing terminal differentiation or apoptosis, in a RA-therapy resistant t(11;17)(q23;q21) APL patient", Oncogene, 18, 1113–1118.
   PubMed Web of Science ®Google Scholar
• Rego, EM., He, L.Z., Warrell, R.P., Jr., Wang, Z.G. and Pandolfi, P.P. (2000) "Retinoic acid (RA) and As203 treatment in transgenic models of acute promyelocytic leukemia (APL) unravel the distinct nature of the leukemogenic process induced by the PML-RARalpha and PLZF-RARalpha oncoproteins", Proc. Natl. Acad. Sci. USA, 97, 10173–10178.
   PubMed Web of Science ®Google Scholar
• Yu, K.H., Weng, Li., Fu, S., Piantadosi, S. and Gore, S.D. (1999) "Augmentation of phenylbutyrate-induced differentiation of myeloid leukemia cells using all-trans retinoic acid", Leukemia, 13, 1258 — 1265.
   Google Scholar
• Taimi, M., Chen, Z.X. and Breitman, T.R. (1998) "Potentiation of retinoic acid-induced differentiation of human acute promyelocytic leukemia NB4 cells by butyric acid, tributyrin, and hexamethylene bisacetamide", Oncol. Res., 10, 75–84.
   Google Scholar
• Calleja, E.M. and Warrell, R.P. (2000) "Differentiating Agents in Pediatric Malignancies: All-trans-Retinoic Acid and Arsenic in Acute Promyelocytic Leukemia", Curr. Oncol. Rep., 2, 519— 523.
   Google Scholar
• Raffoux, E., Rousselot, P., Poupon, J., Daniel, MT., Cassinat, B., Delarue, R., et al. (2003) "Combined treatment with arsenic trioxide and all-trans-retinoic Acid in patients with relapsed acute promyelocytic leukemia", J. Clin. Oncol., 21, 2326–2334.
   Web of Science ®Google Scholar
• Shen, Z.X., Chen, G.Q., Ni, J.H., Li, X.S., Xiong, S.M., Qiu, Q.Y., et al. (1997) "Use of arsenic trioxide (As203) in the treatment of acute promyelocytic leukemia (APL): II. Clinical efficacy and pharmacokinetics in relapsed patients", Blood, 89, 3354— 3360.
   Google Scholar
• Shen, Y., Shen, Z.X., Yan, H., Chen, J., Zeng, X.Y., Li, J.M., et (2001) "Studies on the clinical efficacy and pharmacokinetics of low-dose arsenic trioxide in the treatment of relapsed acute promyelocytic leukemia: a comparison with conventional dosage", Leukemia, 15, 735–741.
   PubMed Web of Science ®Google Scholar
• Jing, Y., Dai, J., Cahlmers-Redman, R.M.E., Tatton, W. and Waxman, S. (1999) "Arsenic trioxide selectively induces acute promyelocytic leukemia cell apoptosis via a hydrogen peroxide dependent pathway", Blood, 94, 2102–2111.
   Google Scholar
• Chen, G.Q., Shi, X.G., Tang, W., Xiong, S.M., Zhu, J., Cai, X., et al. (1997) "Use of arsenic trioxide (As203) in the treatment of acute promyelocytic leukemia (APL): I. As203 exerts dose-dependent dual effects on APL cells", Blood, 89, 3345— 3353.
   Google Scholar
• Jing, Y., Wang, L., Xia, L., Chen, G.Q., Chen, Z., Miller, W.H. and Waxman, S. (2001) "Combined effect of all-trans retinoic acid and arsenic trioxide in acute promyelocytic leukemia cells in vitro and in vivo", Blood, 97, 264–269.
   Google Scholar
• Zhu, J., Chen, Z., Lallemand-Breitenbach, V. and de The, H. (2002) "How acute promyelocytic leukaemia revived arsenic", Nat. Rev. Cancer, 2, 705–713.
   PubMed Web of Science ®Google Scholar
• Cai, X., Shen, Y.-L., Zhu, Q., Jia, P.-M., Yu, Y., Zhou, L., etal. (2000) "Arsenic trioxide-induced apoptosis and differentiation are associated respectively with mitochondrial transmembrane poten-tial collapse and retinoic acid signaling pathways in acute promyelocytic leukemia", Leukemia, 14, 262–270.
   PubMed Web of Science ®Google Scholar
• Lallemand-Breitenbach, V., Guillemin, MC., Janin, A., Daniel, MT., Degos, L., Kogan, S.C., et al. (1999) "Retinoic acid and arsenic synergize to eradicate leukemic cells in a mouse model of acute promyelocytic leukemia", J. Exp. Med., 189, 1043 —1052.
   PubMed Web of Science ®Google Scholar
• Muto, A., Kizaki, M., Kawamura, C., Matsushita, H., Fukuchi, Y., Umezawa, A., et al. (2001) "A novel differentiation-inducing therapy for acute promyelocytic leukemia with a combination of arsenic trioxide and GM-CSF", Leukemia, 15, 1176–1184.
   Google Scholar
• Kizaki, M., Muto, A., Kinjo, K., Ueno, H. and Ikeda, Y. (1998) "Application of heavy metal and cytokine for differentiation-inducing therapy in acute promyelocytic leukemia", J. Natl. Cancer Inst., 90, 1906— 1907.
   Web of Science ®Google Scholar
• Zhu, Q., Zhang, J.W., Zhu, H.Q., Shen, Y.L., Flexor, M., Jia, P.M., et al. (2002) "Synergic effects of arsenic trioxide and cAMP during acute promyelocytic leukemia cell maturation subtends a novel signaling cross-talk", Blood, 99, 1014 — 1022.
   Google Scholar
• Guillemin, M.C., Raffoux, E., Vitoux, D., Kogan, S., Soilihi, H., Lallemand-Breitenbach, V., et al. (2002) "In vivo activation of cAMP signaling induces growth arrest and differentiation in acute promyelocytic leukemia", J. Exp. Med., 196, 1371 — 1380.
   Google Scholar
• Chen, G.Q., Zhou, L., Styblo, M., Walton, F., Jing, Y., Weinberg, R., et al. (2003) "Methylated trivalent arsenicals are potent apoptosis inducers in both acute promyelocytic leukemia and lymphoma cells", Cancer Res., 63, 1853–1859.
   Google Scholar
• Dai, J., Weinberg, R.S., Waxman, S. and Jing, Y. (1999) "Malignant cells can be sensitized to undergo growth inhibition and apoptosis by arsenic trioxide trough modulation of the glutathione redox system", Blood, 93, 268 — 277.
   Google Scholar
• Wang, Z.G., Rivi, R., Delva, L., Konig, A., Scheinberg, D.A., Gambacorti-Passerini, C., et al. (1998) "Arsenic trioxide and melarsoprol induce programmed cell death in myeloid leukemia cell lines and function in a PML and PML-RARalpha independent manner", Blood, 92, 1497 — 1504.
   Google Scholar
• Perkins, C., Kim, C.N., Fang, G. and Bhalla, K.N. (2000) "Arsenic induces apoptosis of multidrug-resistant human myeloid leukemia cells that express Bcr-Abl or overexpress MDR, MRP, Bc1-2, or Bc1-x(L)", Blood, 95, 1014 — 1022.
   Web of Science ®Google Scholar
• La Rosee, P., Johnson, K., O'Dwyer, M.E. and Druker, B.J. (2002) "In vitro studies of the combination of imatinib mesylate (Gleevec) and arsenic trioxide (Trisenox) in chronic myelogenous leukemia", Exp. Hematol., 30, 729–737.
   PubMed Web of Science ®Google Scholar
• Puccetti, E., Guller, S., Orleth, A., Bruggenolte, N., Hoelzer, D., Ottmann, 0.G. and Ruthardt, M. (2000) "BCR-ABL mediates arsenic trioxide-induced apoptosis independently of its aberrant kinase activity", Cancer Res., 60, 3409 — 3413.
   Google Scholar
• El-Sabban, ME., Nasr, R., Dbaibo, G., Hermine, 0., Abboushi, N., Quignon, F., et al. (2000) "Arsenic-interferon-alpha-triggered apoptosis in HTLV-I transformed cells is associated with tax down-regulation and reversal of NF-kappa B activation", Blood, 96, 2849 — 2855.
   Google Scholar
• Mahiewc, R., Pise-Masison, C., Gessain, A., Brady, J.N., Olivier, R., Perret, E., et al. (2001) "Arsenic trioxide induces apoptosis in human T-cell leukemia virus type 1- and type 2-infected cells by a caspase-3-dependent mechanism involving Bc1-2 cleavage", Blood, 98, 3762–3769.
   PubMed Web of Science ®Google Scholar
• Look, A.T. (1997) "Oncogenic transcription factors in the human acute leukemias", Sciences, 278, 1059 — 1064.
   Google Scholar